Clinical Trials Browser

Phase 2 × OTHER × Gynecologic × Clear all

NCT06180356 2026-04-22

ANALLISA

Phase 2 Recruiting

Ovarian Neoplasms

NCT07545746 2026-04-22

Adjuvant 5-Fluorouracil Following Thermal Ablation to Improve HPV Treatment Outcomes in Women With HIV in Kenya

Phase 2 Not yet recruiting

Uterine Cervical Neoplasms, HIV Infections, Papillomavirus Infections

NCT07303387 2026-04-21

EZHiSWITCH

Phase 2 Recruiting

Ovarian Neoplasms

NCT07407647 2026-04-21

Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer

Phase 2 Recruiting

GastrointestinalGynecologic

Anus Neoplasms, Uterine Cervical Neoplasms, Rectal Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

NCT07467772 2026-04-21

Ph 2 Elacestrant in ER Positive Uterine Sarcomas

Phase 2 Recruiting

GynecologicSarcoma

Adenosarcoma of the uterus, Sarcoma, Endometrial Stromal, Perivascular Epithelioid Cell Neoplasms

NCT07340164 2026-04-20

TROY

Phase 2 Recruiting

Ovarian Neoplasms, Recurrence

NCT05123807 2026-04-16

Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)

Phase 2 Recruiting

Ovarian Neoplasms

NCT07223424 2026-04-16

PSI-Immune

Phase 2 Recruiting

DermatologicGastrointestinalGenitourinaryGynecologicThoracic

Adenocarcinoma Of Esophagus, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Colitis, Ulcerative, Colonic Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma

NCT07303894 2026-04-16

A Study of Isoquercetin in People With Ovarian Cancer

Phase 2 Recruiting

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT03682289 2026-04-15

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

Phase 2 Recruiting

GastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Pancreatic Neoplasms, Endometrial Neoplasms

NCT04580771 2026-04-15

A Vaccine (PDS0101) and Chemoradiation for the Treatment of Stage IB3-IVA Cervical Cancer, the IMMUNOCERV Trial

Phase 2 Active not recruiting

Locally Advanced Cervical Squamous Cell Carcinoma, Not Otherwise Specified

NCT06638931 2026-04-15

ANTARES

Phase 2 Recruiting

BreastCNSEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckNETOther solid neoplasmSarcomaThoracic

Urachal adenocarcinoma, Urachal cancer, Fibrolamellar hepatocellular carcinoma, Secretory breast carcinoma, Carcinoma, Ovarian Epithelial, Adrenal Gland Neoplasms, Anus Neoplasms, Biliary Tract Neoplasms, Carcinosarcoma, Carcinoma, Adenoid Cystic, Fallopian Tube Neoplasms, Fibrosarcoma, Gallbladder Neoplasms, Granulosa Cell Tumor, Hemangiosarcoma, Leiomyosarcoma, Mesothelioma, Neuroblastoma, Parathyroid Neoplasms, Penile Neoplasms, Sarcoma, Sarcoma, Kaposi, Osteosarcoma, Thyroid Neoplasms, Trophoblastic Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Hepatoblastoma, Endodermal Sinus Tumor, Neuroectodermal Tumors, Primitive, Cholangiocarcinoma, Sertoli-Leydig Cell Tumor, Neurofibrosarcoma, Hemangioblastoma, Neuroendocrine Tumors

NCT03694262 2026-04-13

EndoBARR

Phase 2 Completed

30 enrolled 7 charts

Endometrial Neoplasms

NCT05183984 2026-04-13

NIRVANA-1

Phase 2 Recruiting

Ovarian Neoplasms

NCT05887609 2026-04-13

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

Phase 2 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06039111 2026-04-13

IGNITE-V

Phase 2 Recruiting

Vulvar Neoplasms

NCT07522697 2026-04-13

MITO END-4

Phase 2 Not yet recruiting

Hereditary Sensory and Autonomic Neuropathies, Endometrial Neoplasms

NCT07107334 2026-04-09

A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia

Phase 2 Recruiting

Endometrial Hyperplasia, Endometrial Neoplasms

NCT07495124 2026-04-08

IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence

Phase 2 Not yet recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07516210 2026-04-07

ART-Hypo

Phase 2 Not yet recruiting

GastrointestinalGenitourinaryGynecologic

Uterine Cervical Neoplasms, Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Endometrial Neoplasms

NCT03428802 2026-04-03

Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability

Phase 2 Active not recruiting

21 enrolled 9 charts

BreastGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms

NCT03612791 2026-04-03

ATEZOLACC

Phase 2 Completed

Locally Advanced Cervical Cancer

NCT03355976 2026-04-02

BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas

Phase 2 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence, Adenocarcinoma, Clear Cell

NCT07290894 2026-04-02

MITO VULVA-01

Phase 2 Recruiting

Vulvar Neoplasms

NCT02873962 2026-04-01

A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib

Phase 2 Active not recruiting

72 enrolled 16 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03614949 2026-04-01

SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer

Phase 2 Active not recruiting

Uterine Cervical Neoplasms

NCT04779554 2026-04-01

Flat Dose vs. Weight-based IP Chemotherapy for CRS/HIPEC

Phase 2 Recruiting

GastrointestinalGynecologic

Appendiceal Neoplasms, Peritoneal Neoplasms, Pseudomyxoma Peritonei, Colorectal Neoplasms

NCT06290193 2026-04-01

Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery

Phase 2 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07377734 2026-03-30

2026ColECFerSp

Phase 2 Recruiting

Endometrial Hyperplasia, Endometrial Neoplasms

NCT02122185 2026-03-27

Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2 Completed

111 enrolled 15 charts

GynecologicThoracic

Carcinoma, Ovarian Epithelial, Brenner Tumor, Fallopian Tube Neoplasms, Pleural Effusion, Malignant

NCT05036681 2026-03-27

A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma

Phase 2 Terminated

9 enrolled 10 charts

Neoplasm Metastasis, Endometrial Neoplasms

NCT07276360 2026-03-27

HypoRTCx-UG

Phase 2 Recruiting

Uterine Cervical Neoplasms

NCT06925724 2026-03-25

A Study of Ivonescimab in People With Endometrial and Cervical Cancers

Phase 2 Recruiting

Uterine Cervical Neoplasms, Endometrial Neoplasms

NCT03617679 2026-03-24

Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer

Phase 2 Completed

79 enrolled 12 charts

Endometrial Neoplasms

NCT07489300 2026-03-24

BACON

Phase 2 Not yet recruiting

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04919629 2026-03-23

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

Phase 2 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05979610 2026-03-23

Reiki-Brachy

Phase 2 Recruiting

Uterine Cervical Neoplasms, Genital Neoplasms, Female, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

NCT04415944 2026-03-19

HIPEC

Phase 2 Completed

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT04430699 2026-03-19

Cisplatin+Pembrolizumab+RT in Vulvar Cancer

Phase 2 Active not recruiting

Vulvar Neoplasms

NCT04016142 2026-03-18

ACCRAPAN

Phase 2 Terminated

Uterine Cervical Neoplasms

NCT07209449 2026-03-18

A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer

Phase 2 Recruiting

Recurrence, Endometrial Neoplasms

NCT02439034 2026-03-16

KETOCOL

Phase 2 Completed

GynecologicHead & Neck

Agnosia, Uterine Cervical Neoplasms, Head and Neck Neoplasms

NCT05231122 2026-03-16

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Phase 2 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05479045 2026-03-16

A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients

Phase 2 Not yet recruiting

Ovarian Neoplasms

NCT00421096 2026-03-13

GEMCOL

Phase 2 Terminated

Uterine Cervical Neoplasms

NCT05521997 2026-03-13

Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer

Phase 2 Not yet recruiting

Uterine Cervical Neoplasms

NCT05758688 2026-03-12

PROPS GYN

Phase 2 Recruiting

Uterine Cervical Neoplasms, Uterine Neoplasms, Endometrial Neoplasms

NCT05763199 2026-03-12

Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®) in Ovarian Cancer Patients on Adjuvant Chemotherapy

Phase 2 Active not recruiting

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT05787561 2026-03-12

A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer

Phase 2 Recruiting

Mesonephric Gynecologic Cancer

NCT07050771 2026-03-12

Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery

Phase 2 Recruiting

GenitourinaryGynecologic

Urinary Bladder Neoplasms, Kidney Neoplasms, Neoplasms, Ovarian Neoplasms